You are here

P&T News

January 23

Report from National Academies reaches mixed conclusions
These and other companies are taking steps to fight antimicrobial resistance
Use of rescue medications also falls in LIBERTY study
After five years, about half of recipients held onto cardiovascular benefits
Most fatalities involved children who didn’t get flu shots

January 22

Eosinophilic asthma drug is currently given based on weight
Under-users tended to be smaller, nonurban, and Western practices
Complete response letter seeks more information on CAM2038
ASP0113 missed key endpoints in phase 3 trial

January 19

32 states experience high activity levels in week ending January 13

January 18

Health systems’ plan is a response to shortages and price hikes
Overall survival rose by about one-third in a European study
Risk of death drops 21% in relapsed or refractory patients
Prostate cancer drug earns $1 billion a year for Janssen
Median PFS more than doubles in CELESTIAL trial

January 16

New pilot program to evaluate disclosure of clinical study reports
New label includes data on three additional EGFR mutations: L861Q, G719X, and S768I
Vaccine was previously approved for patients older than 3 years of age
Head-to-head study compared Cosentyx and Stelara
Analysts predict peak sales of about $8.2 billion by 2020

Pages